Payment overview · 2025
General Payments
$877.43
40 reported records · 20 companies
Healthcare provider profile · identity verified
Sultan Mohammad, MD
Allopathic & Osteopathic Physicians|Family Medicine · BUCKEYE, AZ · NPI 1760699888
Verified facts
What the public records show
CMS Open Payments records show Sultan Mohammad, MD received $877.43 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.37 | 16.2% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $86.45 | 9.8% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $81.84 | 9.3% | 4 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $80.56 | 9.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.78 | 7.7% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $46.66 | 5.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $45.46 | 5.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $43.55 | 5.0% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $42.93 | 4.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $38.01 | 4.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $37.10 | 4.2% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.42 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.86 | 2.4% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.22 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.09 | 2.2% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.51 | 2.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.36 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.28 | 1.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.47 | 1.6% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.51 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $877.43 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $125.07 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $102.06 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $89.12 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $80.56 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $71.82 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $49.82 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $46.66 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $45.46 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.55 | 3 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $42.93 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $37.10 | 2 | 2025 |
Source payment records
|
|||||
| PROCLAIM Normalized: proclaim |
Device | Abbott Laboratories | $32.44 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $30.91 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $27.42 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $22.85 | 1 | 2025 |
Source payment records
|
|||||
| OCTRODE Normalized: octrode |
Device | Abbott Laboratories | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.37 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.36 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $14.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.53 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 86 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
33 | 23 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
138 | 34 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 745 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 445 | 148 |
| Lisinopril | Lisinopril | 404 | 139 |
| Metformin Hcl | Metformin Hcl | 333 | 119 |
| Levothyroxine Sodium | Levothyroxine Sodium | 316 | 83 |
| Losartan Potassium | Losartan Potassium | 266 | 94 |
| Gabapentin | Gabapentin | 223 | 74 |
| Simvastatin | Simvastatin | 208 | 64 |
| Alendronate Sodium | Alendronate Sodium | 193 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 174 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 154 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 153 | 50 |
| Omeprazole | Omeprazole | 146 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 139 | 49 |
| Trulicity | Dulaglutide | 138 | 34 |
| Famotidine | Famotidine | 117 | 34 |
| Trazodone Hcl | Trazodone Hcl | 113 | 45 |
| Furosemide | Furosemide | 107 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 99 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 94 | 42 |
| Glipizide | Glipizide | 92 | 33 |
| Ozempic | Semaglutide | 92 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 29 |
| Clopidogrel | Clopidogrel Bisulfate | 88 | 32 |
| Jardiance | Empagliflozin | 86 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 23 |
| Sertraline Hcl | Sertraline Hcl | 77 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 26 |
| Carvedilol | Carvedilol | 72 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 70 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 17 |
| Glimepiride | Glimepiride | 67 | 22 |
| Januvia | Sitagliptin Phosphate | 63 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 60 | 18 |
| Eliquis | Apixaban | 60 | 23 |
| Allopurinol | Allopurinol | 59 | 20 |
| Lovastatin | Lovastatin | 58 | 20 |
| Meloxicam | Meloxicam | 58 | 21 |
| Methylprednisolone | Methylprednisolone | 58 | 41 |
| Azithromycin | Azithromycin | 54 | 44 |
| Glipizide Er | Glipizide | 54 | 20 |
| Potassium Chloride | Potassium Chloride | 54 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 24 |
| Valsartan | Valsartan | 48 | 13 |
| Donepezil Hcl | Donepezil Hcl | 47 | 19 |
| Metformin Hcl Er | Metformin Hcl | 47 | 15 |
| Nifedipine Er | Nifedipine | 46 | 17 |
| Atenolol | Atenolol | 45 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 45 | 14 |
| Tramadol Hcl | Tramadol Hcl | 44 | 13 |
| Mounjaro | Tirzepatide | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Fenofibrate | Fenofibrate | 39 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 12 |
| Finasteride | Finasteride | 37 | 15 |
| Montelukast Sodium | Montelukast Sodium | 37 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | suppressed |
| Ibuprofen | Ibuprofen | 36 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 34 | 26 |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | 15 |
| Prolia | Denosumab | 33 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 29 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Spironolactone | Spironolactone | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | 13 |
| Naproxen | Naproxen | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 17 |
| Memantine Hcl | Memantine Hcl | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Cephalexin | Cephalexin | 25 | 21 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 13 |
| Multaq | Dronedarone Hcl | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 19 |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 20 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 16 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Lidocaine | Lidocaine | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 12 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Lacosamide | Lacosamide | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $877.43 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ETERNA, FARXIGA, FREESTYLE LIBRE 3, JARDIANCE, KISUNLA, Kerendia, Korlym, LINZESS, LifeVest, NURTEC ODT, OCTRODE, OTEZLA, Ozempic, PROCLAIM, QULIPTA, REPATHA, REXULTI, Rybelsus, UBRELVY, Veozah, WaveWriter Alpha Prime 16, XIFAXAN, ZAVZPRET, ZENPEP, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error